Reacción a "Controversy over the Trump administration's proposal of leucovorin as a treatment for autism"

Leucovorin (folinic acid) has been promoted as a 'treatment' for autism, but the evidence is weak. A few small trials suggest possible small improvements in behavioural outcomes, yet these studies are limited by small numbers, inconsistent findings, and a lack of independent replication. 

Right now, the science does not come close to the standard needed to recommend leucovorin in the clinical management of autism. The field lacks large, multisite, rigorously controlled trials that could confirm whether benefits are real, reproducible, and meaningful in everyday life. 

In short, leucovorin remains experimental. Current research is too narrow and preliminary to draw strong conclusions, and the enthusiasm far outstrips the scientific evidence. Families and clinicians should be cautious, and also know that there are already many support programs with strong scientific backing that reliably support development in autistic children. Compared to these proven approaches, leucovorin is still very much unproven.